Disc Medicine, Inc.

  • Safety Score
  • Market Cap $1.17B
  • PE -11
  • Debt $28.32M
  • Cash $192.67M
  • EV $1.01B
  • FCF -$94.43M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$109.36M
EBIT-$109.00M
ROE-25%
ROA-22%
FCF-$94.43M
Equity$443.59M
Growth Stability1
PE-10.71
PB2.64
P/FCF-12.41
Price/Cash0.16
Debt/Equity0.06
Debt/FCF-0.3
Equity CAGR380%
Earnings Growth YoY25%
Earnings Growth QoQ11%
Equity CAGR 5Y380%
Equity CAGR 3Y84%
Market Cap$1.17B
Assets$496.77M
Total Debt$28.32M
Cash$192.67M
Shares Outstanding27.61M
EV1.01B
Safety Score65%
Working Capital470.3M
Current Ratio21.17
Shares Growth 3y15%
Equity Growth QoQ-5%
Equity Growth YoY29%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of innovative therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The firm's pipeline includes investigational product candidates that affect heme biosynthesis and iron metabolism.

SEC Filings

Direct access to Disc Medicine, Inc. (IRON) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Disc Medicine, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Disc Medicine, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Disc Medicine, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Disc Medicine, Inc..

= -$944M
012345678910TV
fcf-$94M-$94M-$94M-$94M-$94M-$94M-$94M-$94M-$94M-$94M-$94M-$944M
DCF-$86M-$78M-$71M-$64M-$59M-$53M-$48M-$44M-$40M-$36M-$364M
Value-$944M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/202112/202212/202312/2024TTM
Net Margins-----
ROA-49%-23%-21%-22%-22%
ROE-58%-27%-22%-25%-25%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/202112/202212/202312/2024TTM
Debt over FCF---0-0.3-0.3
Debt over Equity0-00.060.06
Growth Stability----1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-----
Earnings YoY growth--35%63%43%-
Equity YoY growth-41%95%29%380%
FCF YoY growth--29%73%28%-